Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IT-CABLE: QL-1706 Combined With Chemotherapy and Bevacizumab as Neoadjuvant Therapy for Locally Advanced Rectal Cancer
NCT07769853Not yet recruiting
- Sponsor
- Zhejiang University
- Start
- Sep 2026
- Primary completion
- Jul 2027
01
Overview
Open-label, single-arm trial of iparomlimab and tuvonralimab in rectal cancer, sponsored by Zhejiang University. Primary endpoints: Clinical Complete Response at 3 weeks and Pathological Complete Response at 1 month. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
iparomlimabtuvonralimab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT07769853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07769853.